Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Drug

Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment

Fineline Cube Dec 13, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...

Company Drug

Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study

Fineline Cube Dec 13, 2023

China-based Suzhou OSAI Biopharma Inc., a specialist in live biotherapeutic products (LBPs), has announced that...

Company Drug

Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the...

Company Drug

BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion

Fineline Cube Dec 12, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...

Company Deals

Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt

Fineline Cube Dec 12, 2023

Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...

Company Drug

Sisram Medical’s Profhilo Accepted for Review by China’s NMPA

Fineline Cube Dec 12, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196),...

Company Drug

Staidson Pharmaceutical Initiates Clinical Study for ARDS Treatment STSA-1002

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing...

Company Medical Device

Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System

Fineline Cube Dec 12, 2023

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Drug

Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns

Fineline Cube Dec 12, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...

Company Medical Device

Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval

Fineline Cube Dec 12, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...

Company Drug

Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA

Fineline Cube Dec 12, 2023

Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...

Company Deals

Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate

Fineline Cube Dec 12, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...

Company Deals

Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine

Fineline Cube Dec 12, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...

Company Deals

Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China

Fineline Cube Dec 12, 2023

Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...

Policy / Regulatory

CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20

Fineline Cube Dec 11, 2023

The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...

Company Drug

Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC

Fineline Cube Dec 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...

Company Deals

Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform

Fineline Cube Dec 11, 2023

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies

Fineline Cube Dec 11, 2023

Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...

Company Deals

Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging

Fineline Cube Dec 11, 2023

Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...

Company Drug

MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints

Fineline Cube Dec 11, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...

Posts pagination

1 … 394 395 396 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.